Vector Development

Scientists Develop Second Generation Lentiviral Gene Delivery System

Published in Blood Weekly, October 6th, 1997

Cell Genesys, Inc., Foster City, California, announced that company scientists, led by Luigi Naldini, M.D., Ph.D., have developed second generation lentiviral vectors for gene therapy which could enhance their application to the treatment of human disease.

The findings, published in the September 1997 issue of Nature Biotechnology, reported that researchers have significantly improved the safety profile of the lentiviral vector by eliminating the five genes associated with virulence, without reducing the efficiency of gene delivery. Among the advantages of lentiviral vectors are their ability to efficiently and stably infect non-dividing cells, such as those comprising...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-10-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry